All World

Biotechs are going back to the Exchange

The biotechs have to score again in stock. As proof, the imminent introduction of Neovacs Deinove and Alternext. Neovacs biotechnology company specializing in immunotherapy (arthritis, Crohn's disease), has extended the period of fifteen days to subscribe for its shares to raise 20 million euros. Deinove, which relies both on green fuels and the production of antibiotics, is preparing to collect 15 million in late April.

"The thrill of the financial markets is clear. The companies that have promising products, attractive valuations and are focusing on big markets again become interesting, "says Dr. Philippe Pouletty, General Partner of Truffle Capital and Honorary Chairman of France Biotech. It was time. Since 2007, this funding, essential for the biotechs, was dry.

Partnerships and acquisitions

The resumption date of late 2009.In November, the biotech NicOx has managed to collect 100 million euros. "Five to six biotech could go public by 2010," predicts Philippe Pouletty. This could be the case Carmat, further participation of Truffle Capital, which is developing an artificial heart, then AB Science, which addresses mastocytosis, a rare disease no teletrack payday loans.

The crisis has not resulted in catastrophe for the biotechs. The decline in venture capital funding has been limited to 25%. The biotech, which have little recourse to debt, were not affected by the closure of the credit tap. At the same time, they took advantage of the growing interest of pharmaceutical companies, forced to look outward to compensate for their lack of internal creativity. The labs have multiplied in recent months partnerships and takeovers."Biotechnology and the green industry are two huge sectors globally. France and the investors have an incentive to participate in this growth, "said Philippe Pouletty. But investors are not always what you. "The performance of biotech on the Paris market is not attractive enough," lamented Francis Deneux, the firm Arthur D. Little. Without doubt, as these start-ups are often financed by public funds including, with "too little selectivity. This leaves the "not enough money for the best of them."

ALSO READ:

A new biofuel with Deinove